BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $ALKS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07455383-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~Brilliance NT1 readout (P3) · Alkermes\, Inc. $ALKS
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adu
 lts With Narcolepsy Type 1\n\nPrimary completion date: 2027-05 (estimated)
  — month only\, shown on the 1st\nPhase 3 · Neuro · Narcolepsy Type 1\
 nEnrollment: 150 · Sites: 66\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07455383\nhttps://clin
 icaltrials.gov/study/NCT07455383
URL:https://datacutoff.com/radar.html?nct=NCT07455383
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502443-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~Brilliance NT2 readout (P3) · Alkermes\, Inc. $ALKS
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adu
 lts With Narcolepsy Type 2\n\nPrimary completion date: 2027-05 (estimated)
  — month only\, shown on the 1st\nPhase 3 · Neuro · Narcolepsy Type 2\
 nEnrollment: 176 · Sites: 61\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT07502443\nhttps://clin
 icaltrials.gov/study/NCT07502443
URL:https://datacutoff.com/radar.html?nct=NCT07502443
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540897-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~ALKS 2680 Dose 1 readout (P3) · Alkermes\, Inc. $ALKS
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety and Tolerability of A
 LKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)\n\nPrimar
 y completion date: 2027-06 (estimated) — month only\, shown on the 1st\n
 Phase 3 · Neuro · Narcolepsy Type 1\nEnrollment: 150 · Sites: 53\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT07540897\nhttps://clinicaltrials.gov/study/NCT07540897
URL:https://datacutoff.com/radar.html?nct=NCT07540897
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755410-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~ALKS 7290 readout (P2) · Alkermes\, Inc. $ALKS
DESCRIPTION:A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared W
 ith Placebo in Adult Participants With Attention Deficit Hyperactivity Dis
 order (ALKS 7290-201)\n\nPrimary completion date: 2027-07 (estimated) — 
 month only\, shown on the 1st\nPhase 2 · Neuro · Attention Deficit Disor
 der With Hyperactivity (ADHD)\nEnrollment: 312 · Sites: 28\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT07755410\nhttps://clinicaltrials.gov/study/NCT07755410
URL:https://datacutoff.com/radar.html?nct=NCT07755410
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04987229-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~OLZ/SAM readout (P3) · Alkermes\, Inc. $ALKS
DESCRIPTION:Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjec
 ts\n\nPrimary completion date: 2027-09 (estimated) — month only\, shown 
 on the 1st\nPhase 3 · Neuro · Bipolar I Disorder\, Schizophrenia\nEnroll
 ment: 236 · Sites: 35\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT04987229\nhttps://clinicaltri
 als.gov/study/NCT04987229
URL:https://datacutoff.com/radar.html?nct=NCT04987229
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
